Showing 2,887 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

PrEP policies & guidelines

U.S. will fulfill Biden-era pledge to provide lenacapavir PrEP to millions

Editor's pick
Science
8 September 2025
Injectable & long-acting PrEP

Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug

Editor's pick
NPR
5 September 2025
Injectable & long-acting PrEP

US: CVS Will Not Cover Long-Acting HIV PrEP Lenacapavir For Now

Editor's pick
POZ
5 September 2025
Injectable & long-acting PrEP

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Editor's pick
Gilead Sciences press release
5 September 2025
Access to healthcare

PrEP Insurance Denials Occur Frequently in U.S., Nationwide Survey Reveals

Editor's pick
TheBodyPro
4 September 2025
Injectable & long-acting PrEP

Twists and turns in the race to be South Africa’s first widely used HIV prevention injection

Editor's pick
Spotlight
4 September 2025
Injectable & long-acting PrEP

Kenya to roll out HIV jab lenacapavir in 2026, not a replacement for anti-retrovirals

Editor's pick
Africa Check
4 September 2025
Injectable & long-acting PrEP

South Africa plans anti-HIV jab roll-out at 300+ clinics by April

Editor's pick
Bhekisisa
28 August 2025
Injectable & long-acting PrEP

EU approves Gilead's new injection for preventing HIV

Editor's pick
Reuters
28 August 2025
Injectable & long-acting PrEP

The EXPrESSIVE Trials Test a Monthly Pill for PrEP: Advocates speak

Editor's pick
AVAC
25 August 2025
PrEP policies & guidelines

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

Editor's pick
FiercePharma
25 August 2025
Injectable & long-acting PrEP

We Have More PrEP Options Than Ever In The U.S.—But Who Will Be Able To Afford Them?

Editor's pick
TheBody
25 August 2025
Finance & funding

NIH ponders overhauling HIV budget to capitalize on prevention breakthrough

Editor's pick
Science Magazine
12 August 2025
Treatment guidelines

IAS 2025: Major updates to WHO guidelines: PrEP, injectable ART, infant feeding and prophylaxis and complications including mpox

Editor's pick
i-Base
9 August 2025
PrEP policies & guidelines

Gilead’s Regulatory Delays Block Access to Lenacapavir for PrEP

Editor's pick
Health GAP (Global Access Project)
4 August 2025
PrEP policies & guidelines

With RFK Jr. reportedly weighing preventive services panel revamp, HIV PrEP drugmakers could be at risk: analysts

Editor's pick
FiercePharma
4 August 2025
Injectable & long-acting PrEP

Lenacapavir PrEP ‘special cases’: young people, missed doses and drug interactions

News
30 July 2025
PrEP

PrEP in Europe

About HIV
July 2025
PrEP policies & guidelines

RFK Jr. reportedly plans to fire the USPSTF for being ‘woke’

Editor's pick
Positively Aware
27 July 2025
Injectable & long-acting PrEP

EMA recommendation on new injection for easier prevention of HIV in the EU and worldwide

Editor's pick
European Medicines Agency
26 July 2025
Injectable & long-acting PrEP

South Africa gets R520-million to buy the twice-a-year anti-HIV jab — but there’s a snag

Editor's pick
Bhekisisa
24 July 2025
Injectable & long-acting PrEP

Does six-monthly PrEP have a future following the collapse of global HIV funding?

News
23 July 2025
Finance & funding

The US cuts challenge African funders and governments to provide new models of PrEP access

News
22 July 2025
Injectable & long-acting PrEP

Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding

News
18 July 2025